In last trading session, CureVac N.V (NASDAQ:CVAC) saw 0.35 million shares changing hands with its beta currently measuring 2.60. Company’s recent per share price level of $2.95 trading at $0.08 or 2.79% at ring of the bell on the day assigns it a market valuation of $661.70M. That closing price of CVAC’s stock is at a discount of -113.56% from its 52-week high price of $6.30 and is indicating a premium of 25.08% from its 52-week low price of $2.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 480.17K if we extend that period to 3-months.
For CureVac N.V (CVAC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.17. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.
CureVac N.V (NASDAQ:CVAC) trade information
CureVac N.V’s shares saw a change of -29.93% in year-to-date performance and have moved 15.23% in past 5-day. CureVac N.V (NASDAQ:CVAC) showed a performance of 5.36% in past 30-days. Number of shares sold short was 4.41 million shares which calculate 9.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29 to the stock, which implies a rise of 89.83% to its current value. Analysts have been projecting 21 as a low price target for the stock while placing it at a high target of 37. It follows that stock’s current price would drop -611.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -611.86% for stock’s current value.
CureVac N.V (CVAC) estimates and forecasts
Statistics highlight that CureVac N.V is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -24.16% of value to its shares in past 6 months, showing an annual growth rate of 147.66% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 885.84% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.5M for the same. And 2 analysts are in estimates of company making revenue of 13.56M in the next quarter. Company posted 22.6M and 12.37M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.15% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 167.50% while estimates for its earnings growth in next 5 years are of -10.76%.
CureVac N.V (NASDAQ:CVAC)’s Major holders
MILLENNIUM MANAGEMENT LLC is the top institutional holder at CVAC for having 2.87 million shares of worth $9.77 million. And as of 2024-06-30, it was holding 1.2809 of the company’s outstanding shares.
The second largest institutional holder is POINT72 ASSET MANAGEMENT, L.P., which was holding about 2.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.0802 of outstanding shares, having a total worth of $8.24 million.
On the other hand, iShares Biotechnology ETF and iShares Core MSCI EAFE ETF are the top two Mutual Funds which own company’s shares. As of Aug 31, 2024 , the former fund manager was holding 687.12 shares of worth $1.97 million or 0.31% of the total outstanding shares. The later fund manager was in possession of 575.4 shares on Sep 30, 2024 , making its stake of worth around $1.65 million in the company or a holder of 0.26% of company’s stock.
